Mizuho Analysts Give Biogen (BIIB) a $400.00 Price Target
The brokerage currently has a buy rating on the biotechnology company's stock. Several other equities analysts also recently weighed in on the stock.
from Biotech News
The brokerage currently has a buy rating on the biotechnology company's stock. Several other equities analysts also recently weighed in on the stock.
The most important thing is to improve and not stop. Even if you have taken some course, this does not mean that you are now a guru. You need to constantly practice, learn something new.
0 Comments